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The burden of vaccine-preventable diseases in pregnancy in 
low-resource settings
Substantial gains have been made globally for many of 
the Millennium Development Goals health targets, but 
progress in the improvement of health has been unequal 
with respect to the most vulnerable populations, 
and major discrepancies persist across regions and 
socioeconomic status. 
Maternal immunisation is a unique opportunity to 
improve maternal and infant health. Vaccines are one of 
the most successful interventions to protect pregnant 
women and their fetuses and infants from diseases that 
cause substantial morbidity and mortality.1,2 However, 
pregnant women have been systematically left out of 
vaccine research, which limits the availability of safety 
and eﬃ  cacy data in pregnancy and, consequently, 
reduces the access of this special population to eﬀ ective 
treatment.2 
Data describing the burden and impact of infections 
in pregnancy, a period that is unique in presentation 
and outcome because of the altered physiology, is 
incomplete and poor.3 A complete understanding of 
the epidemiology of common pathogens such as group 
B streptococcus, respiratory syncytial virus, Bordetella 
pertussis, and inﬂ uenza virus, which can be prevented 
through maternal immunisation, is a priority.3 Little 
is known about the prevalence of these infections in 
pregnancy, and accurate information about the illness 
incidence, its severity, and outcomes is often unavailable. 
Rigorous data collection and adequate clinical and 
epidemiological surveillance systems are needed for 
neonates, young infants, and pregnant women.4 To 
what extent these pathogens contribute to maternal 
morbidity and mortality, and how much the infections 
determine fetal development and perinatal and infant 
survival, are unresolved questions. This information is 
especially needed from low-income countries, where the 
shortage of data is particularly manifest.5,6 
Adequate information about the burden of vaccine-
preventable diseases in pregnancy is needed for several 
reasons: to understand the need for and to advocate 
for such vaccines,7 to monitor the success of their 
implementation, for vaccine optimisation, and to 
improve policy recommendations. Certainly, lessons can 
be learnt from the universal tetanus vaccine strategy, 
which did not necessitate broad burden information 
because the eﬀ ect was clinically evident, or the case of 
the inﬂ uenza vaccine, for which substantial evidence 
arose from several pandemics; in the 2009 inﬂ uenza A 
(H1N1) epidemic, pregnant women were 7·2 times more 
likely than non-pregnant women to get admitted to 
hospital.8 Rigorous and robust burden data will be 
indispensable for making the case for new vaccines 
against pathogens such as group B streptococcus, 
respiratory syncytial virus, and B pertussis, about which 
little is known. Additionally, the role of diseases that are 
highly prevalent in some areas, such as malaria and HIV, 
in modifying the burden and in generating adequate 
immune responses to vaccines during pregnancy is 
important to understand. Placental damage caused by 
these comorbidities, especially malaria, might have a 
role in reducing antibody transfer across the placenta.9,10
Collaborative work between research institutions 
in low and middle-income countries with long 
track records in conducting biomedical research at 
the highest quality standards will be instrumental 
to achieve this goal. These institutions oﬀ er the 
necessary research facilities and infrastructure to 
generate robust evidence from limited resource 
settings and to transform the data into interventions 
with direct beneﬁ ts for the population.11 Examples of 
collaborative work, leading to excellent data gathering 
and documentation of the burden in low-resource 
settings, illustrate their added value in disease burden 
determination and potential for translation into 
policies.12 Likewise, partnerships that bring maternal 
and infant health experts together with the vaccine 
and immunisation communities are crucial.3  Major 
gains can be obtained from the expertise of maternal 
health programmes in understanding the health 
problems aﬀ ecting mothers and their infants, and the 
determinants of success and failure of interventions 
delivered through the antenatal care platform. 
In the next decade, low-income and middle-income 
countries will be introducing new life-saving vaccines 
into their routine immunisation programmes. Maternal 
immunisation has a tremendous potential to improve 
the health of infants during their most vulnerable stages 
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of life. A comprehensive picture of the real burden of 
vaccine-preventable diseases in pregnancy is a necessary 
step for a successful maternal immunisation strategy 
and for the development of maternal immunisation 
policies in high-burden settings. 
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